Paris, France. January 8, 2019 - 7.00 AM CET - Pixium Vision (FR0011950641 - PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to ...
PARIS--(BUSINESS WIRE)--Regulatory News: Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more ...
Pixium Vision completes implantation of PRIMA in five patients with atrophic dry-AMD as expected for the feasibility clinical trial in France Paris, France. July 10, 2018 - 7.00 AM CEST - Pixium ...
Pixium Vision SA (PA:PIX) reported FY18 financials and reiterated that it is on track to start a pivotal study in the EU for its Prima bionic vision system (BVS) in H219 for the treatment of advanced ...
We continue to value Pixium using an rNPV approach, employing a 12.5% cost of capital. Our valuation is based solely on the Prima opportunity in Dry-AMD. We continue to apply a probability of success ...
PRIMA, an unprecedented, innovative and evolutive “brain-machine” interface in ophthalmology PRIMA, bionic vision solution designed for advanced atrophic dry-AMD PRIMA clinical performance to date ...
PARIS--(BUSINESS WIRE)--Regulatory News: Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to enable patients who have lost their sight to lead more ...
Data mark a major step forward in treatment of atrophic AMD Results confirm the safety and stability of the Prima System implant over 24-30 months follow-up Prima System pivotal PRIMAvera study ...
Pixium Vision announces its wireless PRIMA chip successfully met the interim study endpoints for dry Age-related Macular Degeneration Implant is well tolerated while preserving residual peripheral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback